# A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)

> **NCT00196872** · PHASE3 · COMPLETED · sponsor: **GBG Forschungs GmbH** · enrollment: 3000 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Epirubicine
- **DRUG:** Cyclophosphamide
- **DRUG:** Taxol
- **DRUG:** Xeloda
- **DRUG:** Ibandronat

## Key facts

- **NCT ID:** NCT00196872
- **Lead sponsor:** GBG Forschungs GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 3000 (ESTIMATED)
- **Last updated:** 2014-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00196872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00196872, "A Study to Compare ETC vs. EC-TX and Ibandronate vs. Observation in Patients With Node-positive Primary Breast Cancer (GAIN)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00196872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*